Articles
Researchers use a new method to identify potential anticancer drug combinations. Read More ›
Carfilzomib (Kyprolis, Onyx Pharmaceuticals, Inc, South San Francisco, CA) is a selective proteasome inhibitor that irreversibly binds to active sites within the proteolytic core of the 26S proteasome, resulting in inhibition of proteasome activity. Preclinical studies have shown carfilzomib inhibits tumor growth and promotes tumor cell death, with sustained proteasome inhibition for more than 48 hours when using a consecutive-day dosing regimen.1-4
Read More ›ES has received 5 prior lines of therapy, with progression of disease documented on her most recent therapy with a rise in SPEP from 1.3 to 2.2 g/dL and in UPEP from 556 to 1342 mg/24 hours. The current clinical considerations include anemia, renal insufficiency, and PN grade 1 with pain.
Read More ›New study results show that patients who consumed more than 4 cups of caffeinated coffee per day had half the risk of death of oral/pharyngeal cancers compared with those who only occasionally or never drank coffee. Read More ›
Medication reconciliation is a complex and cooperative clinical task required of physicians, nurses and pharmacists in which the goal is to minimize discrepancies and inappropriate medication orders. Read More ›
Women with higher circulating carotenoid levels are at a reduced risk of breast cancer according to recent study results. Read More ›
For patients with HER2-postive early-stage breast cancer, 1 year of adjuvant trastuzumab should remain the standard of care. Read More ›
The FDA recently approved abiraterone acetate, a drug that decreases the production of testosterone, for use in treating men with metastatic castration-resistant prostate cancer prior to receiving chemotherapy. Read More ›
The question of potential overtreatment among women with breast cancer has been raised due to recent studies showing an increase in these patients choosing the more aggressive contralateral prophylactic mastectomy. Read More ›
By adding tomosynthesis, a 3-dimensional (3-D) breast imaging technology, to standard digital mammography, radiologists’ diagnostic accuracy increases while false-positive recall rates decrease Read More ›